The epidemic of nonmelanoma skin cancer and the widespread use of statins: Is there a connection?

Dermato-Endocrinology

Volumn 2, Issue 1, 2010, Pages 37-38

  Mascitelli, Luca ^a   Pezzetta, Francesca ^b   Goldstein, Mark R ^c  

^a Medical Service ^*  (Italy)

^b Ospedale Civile di Tolmezzo   (Italy)

^c Fountain Medical Court ^*  (United States)

Author keywords

Cholesterol; Epidemiology; Immunomodulation; Nonmelanoma skincancer; Risk factors; Statins; Transplantation

Indexed keywords

PLACEBO; SIMVASTATIN; STATIN;

CANCER INCIDENCE; CANCER RISK; CONTROL GROUP; DENDRITIC CELL; DYSLIPIDEMIA; EFFECTOR CELL; HUMAN; IMMUNITY; NONMELANOMA SKIN CANCER; NOTE; RADIATION EXPOSURE; REGULATORY T LYMPHOCYTE; SKIN CANCER; ULTRAVIOLET RADIATION;

EID: 77956305778     PISSN: 19381972     EISSN: 19381980     Source Type: Journal    
DOI: 10.4161/derm.2.1.12128     Document Type: Note

References (19)

1. Rogers HW, Weinstock MA, Harris AR, Hinckley MR, Feldman SR, Fleischer AB, et al. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol 2010; 146:6-7.
2. Gruver AL, Hudson LL, Sempowski GD. Immunosenescence of ageing. J Pathol 2007; 211:144-56.
3. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003; 348:1681-91.
4. Kasiske B, Snyder J, Gilbertson D, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant 2004; 4:905-13. (Pubitemid 38745589)
5. Wimmer CD, Rentsch M, Crispin A, Illner WD, Arbogast H, Graeb C, et al. The janus face of immunosuppression - de novo malignancy after renal transplantation: the experience of the Transplantation Center Munich. Kidney Int 2007; 71:1271-8. (Pubitemid 46887541)
6. Wu JJ, Orengo IF. Squamous cell carcinoma in solid-organ transplantation. Dermatol Online J 2002; 8:4.
7. Brewer JD, Colegio OR, Phillips PK, Roenigk RK, Jacobs MA, Van de Beek D, et al. Incidence of and risk factors for skin cancer after heart transplant. Arch Dermatol 2009; 145:1391-6.
8. Kuklina EV, Yoon PW, Keenan NL. Trends in high levels of low-density lipoprotein cholesterol in the United States, 1999-2006. JAMA 2009; 302:2104-10.
9. Goldstein MR, Mascitelli L, Pezzetta F. The double-edged sword of statin immunomodulation. Int J Cardiol 2009; 135:128-30.
10. Chin C, Lukito SS, Shek J, Bernstein D, Perry SB. Prevention of pediatric graft coronary artery disease: atorvastatin. Pediatr Transplant 2008; 12:442-6. (Pubitemid 351652073)
11. + T cells. Atherosclerosis 2008; 197:829-39.
12. Goldstein MR, Mascitelli L, Pezzetta F. Statins, regulatory T cells, and pediatric graft coronary artery disease. Pediatr Transplant 2009; 13:139-40.
13. Goldstein MR, Mascitelli L, Pezzetta F. Statins, Tregs and cancer. Atherosclerosis 2008; 196:483-4.
14. Mallat Z, Ait-Oufella H, Tedgui A. Regulatory T cell responses: Potential role in the control of atherosclerosis. Curr Opin Lipidol 2005; 16:518-24. (Pubitemid 41376901)
15. Curiel TJ. Tregs and rethinking cancer immunotherapy. J Clin Invest 2007; 117:1167-74.
16. Jang TJ. Prevalence of Foxp3 positive T regulatory cells is increased during progression of cutaneous squamous tumors. Yonsei Med J 2008; 49:942-8.
17. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-9.
18. Heart Protection Study Collaborative Group. MRC/ BHF heart protection study of cholesterol lowering in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:7-22.
19. Ridker PM, Friedewald VE, Davidson MH, Willerson JT, Roberts WC. The Editor's roundtable: The JUPITER Trial - initial results and clinical implications. Am J Cardiol 2009; 103:1417-25.